Cellectis (CLLS) News Today $2.67 +0.08 (+3.09%) Closing price 04:00 PM EasternExtended Trading$2.68 +0.00 (+0.19%) As of 05:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLLS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Cellectis S.A. (NASDAQ:CLLS) Sees Significant Decline in Short InterestAugust 22, 2025 | marketbeat.comCellectis S.A. Earnings Call: Progress Amid ChallengesAugust 10, 2025 | theglobeandmail.comCellectis S.A. Reports Interim Financial Results for First Half of 2025August 6, 2025 | theglobeandmail.comEarnings To Watch: Cellectis SA (CLLS) Reports Q2 2025 ResultAugust 6, 2025 | finance.yahoo.comCellectis (NASDAQ:CLLS) Posts Earnings ResultsAugust 5, 2025 | marketbeat.comCellectis S.A. (CLLS) Q2 2025 Earnings Call TranscriptAugust 5, 2025 | seekingalpha.comCellectis Reports Second Quarter 2025 Financial Results & Business UpdatesAugust 4, 2025 | globenewswire.comCellectis to Announce Q2 2025 Financial Results on August 4July 30, 2025 | theglobeandmail.comCellectis (CLLS) Expected to Announce Quarterly Earnings on TuesdayJuly 29, 2025 | marketbeat.comCellectis to Report Second Quarter 2025 Financial Results on August 4, 2025July 28, 2025 | globenewswire.comBaillie Gifford & Co. Sells 151,382 Shares of Cellectis S.A. (NASDAQ:CLLS)July 27, 2025 | marketbeat.comCellectis (NASDAQ:CLLS) Share Price Crosses Above Fifty Day Moving Average - What's Next?July 4, 2025 | marketbeat.comCellectis files $200M mixed shelf offeringJuly 2, 2025 | msn.comCellectis Reports Results from Shareholders Meeting Held on June 26, 2025 - MorningstarJune 27, 2025 | morningstar.comMCellectis Reports Results from Shareholders Meeting Held on June 26, 2025June 26, 2025 | globenewswire.comCellectis (NASDAQ:CLLS) Stock Passes Below 50 Day Moving Average - Should You Sell?June 26, 2025 | marketbeat.comCellectis (NASDAQ:CLLS) Shares Cross Below 50-Day Moving Average - Time to Sell?June 14, 2025 | marketbeat.comMillennium Management LLC Purchases Shares of 534,551 Cellectis S.A. (NASDAQ:CLLS)June 6, 2025 | marketbeat.comCellectis S.A. (NASDAQ:CLLS) Sees Large Decline in Short InterestJune 2, 2025 | marketbeat.comCellectis (NASDAQ:CLLS) Stock Passes Below 50 Day Moving Average - Here's What HappenedMay 31, 2025 | marketbeat.comCellectis’s SWOT analysis: gene therapy firm’s stock faces pivotal yearMay 29, 2025 | investing.comWall Street Zen Downgrades Cellectis (NASDAQ:CLLS) to SellMay 24, 2025 | marketbeat.comCellectis S.A. announces board change and meetingMay 22, 2025 | investing.comCellectis' Annual Shareholders General Meeting to be Held on June 26, 2025May 21, 2025 | globenewswire.comCellectis: Partnerships And Promised Data In 2025 Continue To Justify The BuyMay 15, 2025 | seekingalpha.comStockNews.com Downgrades Cellectis (NASDAQ:CLLS) to HoldMay 14, 2025 | marketbeat.comCellectis (NASDAQ:CLLS) Releases Quarterly Earnings ResultsMay 14, 2025 | marketbeat.comCellectis Reports Financial Results for the First Quarter 2025May 13, 2025 | finance.yahoo.comCellectis Reports Financial Results for the First Quarter 2025May 12, 2025 | globenewswire.comCellectis to Report First Quarter Financial Results on May 12, 2025May 6, 2025 | globenewswire.comCellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual MeetingApril 29, 2025 | finance.yahoo.comCellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual MeetingApril 28, 2025 | globenewswire.comCellectis (NASDAQ:CLLS) Upgraded at StockNews.comApril 27, 2025 | marketbeat.comB Group Inc. Buys Shares of 3,081,501 Cellectis S.A. (NASDAQ:CLLS)April 23, 2025 | marketbeat.comCellectis Charts Course for 2025 With Boost From AstraZeneca DealCellectis, backed by AstraZeneca funding and a multi-year cash runway, is advancing its prioritized allogeneic CAR-T pipeline toward pivotal 2025 milestones.April 22, 2025 | marketbeat.comShort Interest in Cellectis S.A. (NASDAQ:CLLS) Grows By 107.2%April 18, 2025 | marketbeat.comCellectis (NASDAQ:CLLS) Rating Increased to Buy at StockNews.comApril 10, 2025 | marketbeat.comCellectis (NASDAQ:CLLS) Raised to Buy at StockNews.comApril 1, 2025 | marketbeat.comCellectis (NASDAQ:CLLS) Rating Lowered to "Hold" at StockNews.comMarch 20, 2025 | marketbeat.comCellectis (NASDAQ:CLLS) Announces Earnings ResultsMarch 16, 2025 | marketbeat.comCellectis Reports 2024 Financial Results and Strategic AdvancesMarch 14, 2025 | tipranks.comCellectis S.A. Earnings Call Highlights Strategic GrowthMarch 14, 2025 | tipranks.comCellectis S.A. (CLLS) Q4 2024 Earnings Call TranscriptMarch 14, 2025 | seekingalpha.comBarclays Sticks to Their Buy Rating for Cellectis SA (CLLS)March 14, 2025 | markets.businessinsider.comCellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business UpdateMarch 14, 2025 | markets.businessinsider.comCellectis reports Q4 EPS (64c) vs (17c) last yearMarch 14, 2025 | markets.businessinsider.comCellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business UpdateMarch 13, 2025 | globenewswire.comCellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025March 7, 2025 | globenewswire.comCellectis (NASDAQ:CLLS) Share Price Crosses Below 50-Day Moving Average - Here's WhyFebruary 28, 2025 | marketbeat.comStockNews.com Begins Coverage on Cellectis (NASDAQ:CLLS)February 27, 2025 | marketbeat.com Get Cellectis News Delivered to You Automatically Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLLS Media Mentions By Week CLLS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLLS News Sentiment▼1.880.97▲Average Medical News Sentiment CLLS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLLS Articles This Week▼21▲CLLS Articles Average Week Get the Latest News and Ratings for CLLS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Cellectis and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies KROS News MGTX News MRVI News TYRA News ORGO News RZLT News TERN News XNCR News TRML News MAZE News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLLS) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access